tailieunhanh - báo cáo khoa học: " Pharmacogenomic insights into treatment and management of statin-induced myopathy"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Pharmacogenomic insights into treatment and management of statin-induced myopathy | Genome Medicine Review Pharmacogenomic insights into treatment and management of statin-induced myopathy Bas JM Peters Olaf H Klungel Frank L Visserent Anthonius de Boer and Anke-Hilse Maitland-van der Zee Addresses Department of Pharmacoepidemiology and Pharmacotherapy Utrecht Institute for Pharmaceutical Sciences UIPS University of Utrecht 3508 TB Utrecht The Netherlands. Department of Vascular Medicine University Medical Centre Utrecht 3508 GA Utrecht The Netherlands. Correspondence Anke-Hilse Maitland-van der Zee. Email Abstract Although statins are generally well tolerated the most common adverse drug reaction from statin therapy is myopathy. This article reviews the current pharmacogenomic knowledge of statin-induced myopathy. Furthermore we will discuss the importance of recent pharmacogenetic advances for the treatment and management of statin-induced myopathy. Variation in the SLCO1B1 gene is associated with increased incidence of statin-induced myopathy particularly with simvastatin and less so with other statins. If different pharmacokinetic enzymes and transporters are responsible for susceptibility to myopathy this may explain differences in the occurrence of statin-induced myopathy in individual patients. Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin for the lowest chance of developing myopathy. Introduction To reduce the morbidity and mortality associated with heart disease 3-hydroxy-3-methylglutaryl coenzyme A HMG-CoA inhibitors statins are used by millions of patients worldwide. The primary mechanism by which statins reduce the risk of coronary artery disease CAD involves lowering low-density lipoprotein cholesterol LDLc in plasma. Although generally well tolerated the most common adverse drug reaction ADR from statin therapy is myopathy symptoms of which can range from myalgia mild fatigue and muscle pain without raised creatine kinase CK 1 to life-threatening .